Latest news
25 items- PRLantern Pharma Announces Appointment of Dr. Lee Schalop to Board of DirectorsSeasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member
- SECSEC Form 15-12G filed by Chimerix Inc.15-12G - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form EFFECT filed by Chimerix Inc.EFFECT - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form S-8 POS filed by Chimerix Inc.S-8 POS - CHIMERIX INC (0001117480) (Filer)
- SECSEC Form POS AM filed by Chimerix Inc.POS AM - CHIMERIX INC (0001117480) (Filer)
- INSIDERSEC Form 4 filed by Director Vakiener Victoria4 - CHIMERIX INC (0001117480) (Issuer)
- INSIDERChief Executive Officer Sherman Michael A. returned $3,620,138 worth of shares to the company (423,408 units at $8.55), closing all direct ownership in the company (SEC Form 4)4 - CHIMERIX INC (0001117480) (Issuer)
- SECChimerix Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - CHIMERIX INC (0001117480) (Filer)
- INSIDERCOO and CCO Riga Thomas J returned $520,079 worth of shares to the company (60,828 units at $8.55), closing all direct ownership in the company (SEC Form 4)4 - CHIMERIX INC (0001117480) (Issuer)
- INSIDERSEC Form 4 filed by Director Multani Pratik S4 - CHIMERIX INC (0001117480) (Issuer)
- INSIDERDirector Middleton Fred A returned $30,912,328 worth of shares to the company (3,615,477 units at $8.55), closing all direct ownership in the company (SEC Form 4)4 - CHIMERIX INC (0001117480) (Issuer)
- INSIDERDirector Meyer Robert J. returned $300,532 worth of shares to the company (35,150 units at $8.55), closing all direct ownership in the company (SEC Form 4)4 - CHIMERIX INC (0001117480) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Melemed Allen S. returned $1,486,435 worth of shares to the company (173,852 units at $8.55), closing all direct ownership in the company (SEC Form 4)4 - CHIMERIX INC (0001117480) (Issuer)
CMRX FAQ
7 questionsWhat does Chimerix Inc. do?
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which...Where does CMRX stock trade?
Chimerix Inc. (CMRX) is listed on NASDAQ.What sector and industry is CMRX in?
Chimerix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Chimerix Inc. go public?
Chimerix Inc. (CMRX) completed its IPO in 2013.What are analysts saying about CMRX?
Chimerix Inc. has had 4 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $700.00 price target on 2023-05-23. Recent price targets range from $700.00 to $2400.00.What companies are similar to CMRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CMRX side-by-side with any of them on Quantisnow.How can I track CMRX on Quantisnow?
Quantisnow aggregates Chimerix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMRX to receive live email and push alerts on every new disclosure.